Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting
نویسندگان
چکیده
منابع مشابه
Meeting report: Translational Research at the Aging and Cancer Interface.
Buck Institute for Age Research, Novato, California; Lawrence Berkeley National Laboratory, Berkeley, California; Duke University Medical Center and VA Medical Centers, Durham, North Carolina; National Institute on Aging, Baltimore, Maryland; University Hospitals of Geneva, Geneva, Switzerland; and Task Force on Cancer and Aging, American Association for Cancer Research, Philadelphia, Pennsylvania
متن کاملMeeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
Addressing genetics, risk modeling, molecular targets for chemoprevention, clinical prevention trials, behavioral prevention research, public policy, and more, the Fifth Annual International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts, in November 2006, added an outstanding new chapter to the landmark AACR Frontiers program for advancing the science and ...
متن کاملAdvances in meeting recognition
Speech recognition has advanced considerably, but has been limited almost entirely either to situations in which close speaking microphones are natural and acceptable (telephone, dictation, command&control, etc.) or in which high-quality recordings are ensured. Furthermore, most recognition applications involve controlled recording environments, in which the user turns the recognition event on ...
متن کاملMeeting Report Eye development at the Houston "Fly Meeting"
The Genetics Society of America (GSA) organizes an annual meeting for Drosophila researchers from all over the world who work on overlapping or closely related fields, for interaction and exchange of ideas. The 47th Annual Drosophila Research Conference was organized at Houston, Texas, USA by Hugo J. Bellen, Ron Davis, Graeme Mardon (Baylor College of Medicine) and Georg Halder (M.D. Anderson C...
متن کاملMeeting Report Cancer Immunotherapy Highlights from the 2014 ASCO Meeting
The promise of cancer immunotherapy was validated officially in March 2011 when the FDA approved Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of unresectable ormetastatic melanoma. The approval was based on results of a randomized, double-blind clinical trial establishing that ipilimumab (a humanized antiCTLA-4 monoclonal antibody) treatment extended the overall survival of patie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer Prevention
سال: 2021
ISSN: 2288-3649,2288-3657
DOI: 10.15430/jcp.2021.26.1.71